/PRNewswire/ Life Molecular Imaging (LMI) is pleased to announce the publication of a significant retrospective analysis utilizing the amyloid positron.
Group chief executive Peter Wharton-Hood says the healthcare company has allocated a capex spend of R1.6bn on international maintenance and growth projects.
Johannesburg Stock Exchange-listed health group Life Healthcare on Thursday announced its results for the six months ending on March 31 this year. The group operates 66 healthcare facilities in South and Southern Africa and owns the leading independent medical imaging services provider in the UK and Europe, namely the Alliance Medical Group (AMG). “We have again shown solid operational performance across all markets, maintaining momentum, and making steady progress in executing on our long-term strategy,” affirmed Life Healthcare Group CEO Peter Wharton-Hood. “We remain well-positioned for sustainable growth in 2023 and beyond.”
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein